SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

27 May 2024 Evaluate
The sales moved up 34.60% to Rs. 3831.99 millions for the March 2024 quarter as compared to Rs. 2847.04 millions during the year-ago period.The Total revenue for the quarter ended March 2024 of  Rs. 394.78  millions  grew by 128.58% from Rs. 172.71 millions.Operating profit for the quarter ended March 2024 decreased to 581.18 millions as compared to 678.46 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 3831.99 2847.04 34.60 12955.28 10029.71 29.17 12955.28 10029.71 29.17
Other Income 87.30 79.97 9.17 348.00 261.02 33.32 348.00 261.02 33.32
PBIDT 581.18 678.46 -14.34 2192.52 1912.27 14.66 2192.52 1912.27 14.66
Interest 0.00 0.88 0.00 12.01 6.33 89.73 12.01 6.33 89.73
PBDT 581.18 275.29 111.12 2344.77 1503.65 55.94 2344.77 1503.65 55.94
Depreciation 37.64 42.49 -11.41 149.40 162.60 -8.12 149.40 162.60 -8.12
PBT 543.54 232.80 133.48 2195.37 1341.05 63.71 2195.37 1341.05 63.71
TAX 148.76 60.09 147.56 580.28 348.12 66.69 580.28 348.12 66.69
Deferred Tax -6.39 -23.73 -73.07 -9.03 -34.90 -74.13 -9.03 -34.90 -74.13
PAT 394.78 172.71 128.58 1615.09 992.93 62.66 1615.09 992.93 62.66
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 15.17 23.83 -36.36 16.92 19.07 -11.24 16.92 19.07 -11.24

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×